Atara stock plunges 50% after-hours on failed Phase 2 study for MS drug (ATRA)


Multiple sclerosis (multiple sclerosis) a disease that affects the nervous system, written on wooden blocks, health concept, rare disease detection and treatment, lettering on puzzle pieces

Andrzej Rostek/iStock via Getty Images

Atara Biotherapeutics (NASDAQ:ATRA) stock plunged 50% in after-hours trading Wednesday after the company said that a Phase 2 study for its drug ATA188 in the treatment of multiple sclerosis failed to meet its primary endpoint.

Atara said it is evaluating

Source link

Leave A Reply

Your email address will not be published.